Overview

Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

Status:
Terminated
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.
Phase:
Phase 3
Details
Lead Sponsor:
Hospira, Inc.
Hospira, now a wholly owned subsidiary of Pfizer
Treatments:
Ketamine